International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Progressive advancement and Technological modification in transdermal drug delivery system

VISHAL SARJERAO PATIL, MUBEEN ANSARI

Abstract:

Transdermal Drug Delivery Systems (TDDS) have emerged as a promising alternative to conventional drug administration routes due to their ability to deliver therapeutic agents directly through the skin into systemic circulation, thereby improving patient compliance and minimizing gastrointestinal side effects. Over the past few decades, TDDS have undergone significant technological advancements, transitioning from simple patches to highly sophisticated systems incorporating microneedles, iontophoresis, sonophoresis, and nanocarriers. These innovations have not only expanded the range of drugs that can be effectively delivered trans dermally but have also enhanced drug permeation, controlled release, and targeted delivery.

The progressive development of skin permeation enhancers and biocompatible polymers has played a crucial role in overcoming the skin's natural barrier—the stratum corneum.

Furthermore, the integration of nanotechnology has led to the creation of lipid-based carriers such as liposomes, niosomes, and solid lipid nanoparticles, offering improved stability, drug loading, and sustained release profiles. Wearable electronic TDDS, including smart patches, have also revolutionized patient-centric healthcare by enabling real-time monitoring and personalized drug delivery.

Introduction

The transdermal drug delivery system (TDDS) represents a significant evolution in the field of pharmaceutics, offering a non-invasive and controlled method for administering therapeutic agents through the skin. Over the past few decades, TDDS has gained considerable attention due to its potential to bypass the gastrointestinal tract, avoid firstpass metabolism, and maintain consistent plasma drug levels. As an alternative to conventional drug administration routes like oral or injectable forms, TDDS enhances patient compliance, particularly in chronic therapies where long-term medication adherence is critical.

Recent years have witnessed remarkable advancements and technological modifications in TDDS, driven by the need for improved drug efficacy, safety, and patient-centric solutions. The evolution from passive delivery systems—such as patches relying on natural skin permeability— to more sophisticated active technologies, like iontophoresis, microneedles, sonophoresis, and nanocarriers, has expanded the range of deliverable drugs, including peptides, proteins, and vaccines. These innovations address key challenges such as limited skin permeability, drug stability, and targeted delivery, enabling more precise and efficient therapeutic outcomes.

Moreover, the integration of smart technologies and materials into transdermal systems has further transformed the landscape of drug delivery. Wearable patches embedded with biosensors, programmable release mechanisms, and feedback-controlled systems are at the forefront of personalized medicine. These intelligent TDDS platforms not only administer drugs but also monitor physiological responses, ensuring real-time adjustment of dosing and improving treatment outcomes.

This review aims to explore the progressive advancements and technological modifications in TDDS, highlighting key developments, mechanisms, applications, and future perspectives. By delving into the evolution of TDDS from conventional approaches to cutting-edge innovations, this study underscores its pivotal role in shaping the next generation of drug delivery solutions.

Basic Mechanisms of TDDS

Structure and Function of the Skin in Drug Delivery

The skin is composed of three main layers: the epidermis, dermis, and hypodermis. The epidermis consists primarily of keratinocytes and is the outermost protective layer. The stratum corneum, which is the outermost layer of the epidermis, plays a vital role in regulating drug penetration. Underneath, the dermis contains blood vessels that facilitate the absorption of drugs into systemic circulation.

How Drugs Are Absorbed Through the Skin

For effective TDDS, the drug must penetrate the skin's stratum corneum. This process is influenced by several factors, including molecular size, lipophilicity (fat solubility), and the use of enhancers that can temporarily disrupt the skin's barrier function. Once the drug passes through the stratum corneum, it enters the viable epidermis and dermis, where it is absorbed into the bloodstream.

Factors Affecting Drug Absorption

- **Molecular Size**: Small molecules are more easily absorbed through the skin compared to larger molecules.
- **Solubility**: Lipophilic (fat-soluble) drugs are generally more efficiently absorbed compared to hydrophilic (water-soluble) drugs.
- **Skin Condition**: The presence of skin damage or conditions like eczema can alter the permeability of the skin and affect drug absorption.
- **Temperature and Humidity**: These factors can influence the rate at which drugs are absorbed.

Fundamentals of Transdermal Drug Delivery

Structure and Function of the Skin

The skin is the body's largest organ and acts as a barrier to the entry of foreign substances. It consists of three main layers:

- **Epidermis**: The outermost layer, which is composed primarily of keratinocytes and serves as a barrier.
- **Dermis**: Beneath the epidermis, this layer contains blood vessels, nerves, and connective tissue.
- **Hypodermis**: The deepest layer, which is mainly composed of fat cells.

For TDDS, drugs must penetrate the skin's outermost layer, the epidermis, before reaching the bloodstream. The skin's stratum corneum (outermost layer of the epidermis) poses a significant barrier to drug penetration. The effectiveness of a transdermal delivery system is determined by its ability to overcome this barrier.

Mechanisms of Drug Absorption Through the Skin

Drugs can be delivered through the skin via several pathways:

- **Intercellular Pathway**: The drug passes between the cells in the stratum corneum.
- **Intracellular Pathway**: The drug passes through the cells.
- **Hair Follicles and Sweat Glands**: These routes offer some resistance but can still contribute to drug absorption.

The rate at which a drug penetrates the skin depends on its molecular size, lipophilicity (fat solubility), and concentration gradient. The drug must be small enough to pass through the skin layers and must be able to diffuse through the skin's lipid environment.

Challenges in TDDS

Several factors influence the performance of TDDS:

- **Skin Permeability Variability**: The permeability of skin varies from person to person and even between different areas of the body.
- **Limited Drug Loading**: The amount of drug that can be incorporated into a transdermal patch is limited by the skin's permeability and the size of the patch.
- **Poor Solubility of Some Drugs**: Some drugs have low solubility in the skin's lipid layers, making them difficult to deliver effectively.
- **Rate of Drug Release**: Ensuring that drugs are released at a steady and controlled rate is a challenge in patch design.

Benefits of TDDS Over Other Delivery Systems

- **Bypass of the First-Pass Effect**: Drugs administered through TDDS avoid metabolism in the liver, which is common with oral drugs, ensuring that more of the active drug reaches systemic circulation.
- **Sustained Release**: TDDS can release drugs over an extended period, providing consistent blood levels and improving therapeutic efficacy.
- **Non-Invasive**: Unlike injections or oral drugs, TDDS offers a non-invasive route of administration, which is more comfortable for patients, especially those with chronic conditions.
- **Improved Patient Compliance**: Due to ease of use and the steady release of medication, patient adherence to prescribed treatments tends to improve.

Overview of Transdermal Drug Delivery Systems (TDDS)

Transdermal Drug Delivery Systems (TDDS) represent a progressive approach in the pharmaceutical field, allowing the administration of therapeutic agents through the skin for systemic effects. Unlike conventional drug delivery routes such as oral or injectable forms, TDDS bypasses the gastrointestinal tract and first-pass hepatic metabolism, offering improved bioavailability, controlled drug release, and enhanced patient compliance.

The fundamental concept of TDDS lies in its ability to deliver drugs across the skin barrier into the systemic circulation. The human skin, particularly the outermost layer called the stratum corneum, poses a significant barrier to drug permeation due to its densely packed keratinized cells and lipophilic nature. Effective TDDS formulations are designed to overcome this barrier using specialized technologies and formulations that enhance drug penetration without compromising skin integrity.

TDDS is typically composed of several key components, including a drug reservoir or matrix, a polymeric adhesive, a backing layer, and sometimes a rate-controlling membrane. These systems can be engineered to release drugs at a steady rate over a prolonged period, reducing dosing frequency and maintaining therapeutic plasma concentrations. Patches are the most common form of TDDS, offering non-invasive administration and convenience for long-term treatments.

The development of TDDS began with passive systems like reservoir and matrix patches, which relied on drug diffusion driven by concentration gradients. Over time, significant advancements have been made, leading to the emergence of active TDDS. These include technologies such as iontophoresis, sonophoresis, electroporation, and microneedles, which use physical or chemical methods to enhance skin permeability and enable the delivery of large or hydrophilic molecules.

TDDS has found widespread applications in various therapeutic areas including pain management (e.g., fentanyl patches), hormone replacement therapy (e.g., estrogen and testosterone patches), smoking cessation (e.g., nicotine patches), cardiovascular conditions, and central nervous system disorders. Its ability to provide a controlled release of medication makes it particularly useful for chronic diseases requiring consistent drug levels.

One of the key advantages of TDDS is the reduction in systemic side effects commonly associated with oral drugs, as lower doses are needed to achieve the same therapeutic effect. It also eliminates the discomfort and risk of infection associated with injections. However, TDDS is not without limitations. Only drugs with certain physicochemical properties, such as low molecular weight, adequate lipophilicity, and high potency, are suitable for transdermal delivery. Additionally, variability in skin conditions, irritation, and slow onset of action are potential drawbacks.

In recent years, the integration of nanotechnology, smart wearable devices, and biosensors has transformed TDDS into a more responsive and personalized system. Innovations such as microneedle arrays, bio responsive hydrogels, and smartphonecontrolled patches are paving the way for the next generation of transdermal systems.

In conclusion, TDDS has emerged as a versatile and patient-friendly platform in modern drug delivery. As research continues to address its limitations and expand its capabilities, TDDS is expected to play an increasingly important role in personalized medicine and chronic disease management.

Technological Modifications and Advancements in Transdermal Drug Delivery Systems (TDDS)

Transdermal Drug Delivery Systems (TDDS) have evolved significantly since their inception, transforming from basic drug-in-adhesive patches into highly advanced delivery platforms integrated with nanotechnology, micro-devices, and controlled release systems. Technological modifications and advancements have greatly enhanced drug permeation, bioavailability, patient compliance, and the range of drugs that can be delivered via the skin.

This section explores the cutting-edge technological improvements that have shaped the current and next-generation TDDS.

1. Limitations of Conventional TDDS and Need for Advancements

Traditional TDDS are primarily suitable for delivering low molecular weight, lipophilic drugs at low doses. Despite their advantages, conventional patches face significant challenges:

Poor permeability of large or hydrophilic molecules

Variability in skin barrier function across individuals

Inability to deliver high-dose or macromolecular drugs (e.g., peptides, proteins, vaccines)

Lag time in drug absorption

Limited control over drug release kinetics

These limitations have led researchers to develop technologically advanced TDDS that can overcome the stratum corneum barrier, provide controlled drug release, and expand the spectrum of deliverable drugs.

2. Advanced TDDS Technologies

A. Microneedle Systems

Microneedles are tiny projections (ranging from 50–900 µm in length) that penetrate the stratum corneum without reaching the pain receptors in the dermis.

Types of Microneedles:

- Solid Microneedles: Used to pre-treat skin for enhanced drug absorption.
- Coated Microneedles: Drug is coated onto microneedles and dissolves after insertion.
- Dissolving Microneedles: Made from biodegradable polymers loaded with drug.
- Hollow Microneedles: Allow controlled infusion of liquid drugs.

Advantages:

- Painless administration
- Suitable for vaccines, peptides, insulin, and hormones
- Fast onset and targeted delivery

Microneedle patches like MicronJet and Zosano Pharma's Qtrypta have shown great promise in clinical trials.

B. Iontophoresis

Iontophoresis uses a low-intensity electric current to enhance drug delivery across the skin. Charged drug molecules are repelled into the skin by electrodes.

Applications:

- Pain management (e.g., fentanyl)
- Hormonal therapies Anti-inflammatory agents

Advantages:

- Controlled drug delivery
- Enhances delivery of ionic and polar drugs
- Non-invasive and patient-friendly
- Devices like Ionsys (fentanyl iontophoretic patch) have already received FDA approval.

C. Sonophoresis (Ultrasound-Enhanced Delivery)

Sonophoresis uses high-frequency ultrasound waves to temporarily disrupt the skin structure and enhance drug transport.

Mechanism:

- Acoustic cavitation (formation and collapse of gas bubbles) increases skin permeability.
- Enhances the delivery of both hydrophilic and high-molecular-weight drugs.

Applications:

Delivery of insulin, local anesthetics, and anti-inflammatory drugs.

D. Electroporation

Electroporation applies short, high-voltage pulses to create transient aqueous pores in the stratum corneum.

Advantages:

- Facilitates delivery of large molecules, such as DNA, RNA, and vaccines.
- Rapid drug transport into deeper skin layers.
- Gene therapy
- Cancer immunotherapy
- DNA-based vaccines

E. Thermal and Radiofrequency-Based TDDS

- These technologies create micropores in the skin using thermal energy or radiofrequency waves.
- Thermal ablation: Involves controlled heating to remove the stratum corneum without damaging deeper tissues.
- Radiofrequency ablation: Uses electrical currents to form microchannels.
- Devices: ViaDerm (TransPharma), Symphony (Echo Therapeutics)

3. Nanotechnology-Based TDDS

Nanotechnology has revolutionized TDDS by enabling the delivery of poorly soluble, unstable, or large-sized drugs.

A. Liposomes

Liposomes are phospholipid bilayer vesicles capable of encapsulating both hydrophilic and lipophilic drugs.

Advantages:

- Improved drug stability
- Enhanced skin permeation
- Targeted and sustained release

B. Niosomes

Non-ionic surfactant-based vesicles similar to liposomes but more stable and costeffective.

Hormone delivery (e.g., estradiol) Anti-aging and skin-care agents

C. Solid Lipid Nanoparticles (SLNs)

SLNs are submicron colloidal carriers made from solid lipids.

Advantages:

- Controlled drug release

- Protection of labile drugs
- Enhanced bioavailability

D. Nanogels and Nanoemulsions

Nanogels are hydrophilic polymer networks with excellent swelling properties, while nanoemulsions are thermodynamically stable dispersions.

Benefits:

- Enhanced solubilization
- Improved permeation and retention
- Ease of application on the skin

4. Smart and Responsive TDDS

Next-generation TDDS are being developed with stimuli-responsive capabilities—they release the drug in response to specific internal or external stimuli such as:

- pH
- Temperature
- Enzymes
- Magnetic fields
- Light

Example:

Glucose-responsive insulin patches that release insulin when glucose levels rise.

These systems provide precision drug delivery and reduce the risk of side effects.

4. 3D-Printed TDDS

With the advent of 3D printing, customizable transdermal patches can be developed for patientspecific treatments.

Advantages:

- Precision drug loading
- Tailored patch geometry
- On-demand manufacturing
- Polymers like PVA, PLA, and hydrogels are commonly used in 3D-printed TDDS research.

5. Biodegradable and Eco-Friendly TDDS

Traditional TDDS may generate medical waste. Newer research focuses on biodegradable patches using natural polymers like:

- Chitosan
- Gelatin
- Alginate

These systems degrade naturally after drug delivery, offering a more sustainable and ecoconscious option.

6. Integration with Wearable Electronics

Integration of TDDS with wearable biosensors and electronic devices enables real-time monitoring and feedback-controlled drug delivery.

Example:

- Smart insulin patches monitor glucose levels and release insulin accordingly.
- Bluetooth-enabled patches to track drug release and adherence.
- This synergy between drug delivery and digital health is revolutionizing personalized medicine.

7. Transdermal Delivery of Biologics and Vaccines

Recent breakthroughs have enabled the delivery of large biologics—peptides, proteins, and nucleic acids—using TDDS.

- Technologies enabling this:
- Microneedle arrays
- Electroporation
- Nanoformulations

COVID-19 and flu vaccine patches using microneedles are already being trialed for mass immunization strategies.

8. Regulatory Approvals and Commercial Products

Several advanced TDDS products have already received regulatory approvals:

- Ionsys® – Iontophoretic fentanyl system
- Qutenza® – Capsaicin patch using high-concentration therapy
- Zecuity® – Iontophoretic sumatriptan patch
- Twicetouch™ – Electroporation-based drug delivery system

The successful commercialization of these products demonstrates the real-world impact of technological advancements.

Recent Innovations in Transdermal Drug Delivery Systems (TDDS)

The field of Transdermal Drug Delivery Systems (TDDS) has undergone remarkable transformation in recent years, driven by a need for more efficient, patient-friendly, and versatile drug administration methods. Innovations in science and technology have enabled the development of next-generation TDDS capable of delivering a wider range of therapeutic agents—including large biomolecules, vaccines, and gene therapies—while overcoming the challenges of conventional patches. These advancements not only enhance drug bioavailability and therapeutic outcomes but also significantly improve user compliance and system safety.

This section explores the most recent and impactful innovations in TDDS.

1. Dissolving and Biodegradable Microneedle Patches

Microneedle (MN) technology has become one of the most promising innovations in TDDS. Recent advances have focused on dissolving microneedles made from biodegradable polymers that completely dissolve in the skin after drug delivery.

Key Benefits:

- Eliminate sharp waste and need for disposal
- Provide painless and precise delivery
- Enable delivery of macromolecules (insulin, vaccines, peptides)
- Recent Developments:
- Glucose-responsive insulin microneedles that release insulin only when glucose levels rise.
- COVID-19 vaccine microneedles for simplified mass immunization.
- Self-dissolving microneedle arrays for anti-cancer drugs, such as doxorubicin and paclitaxel.

2. Smart TDDS with Integrated Sensors and Feedback Mechanisms

- Modern TDDS are being combined with biosensors and digital health tools to enable realtime monitoring and automatic drug delivery.
- Examples of Smart TDDS:
- Closed-loop insulin patches: These detect blood glucose levels and release insulin accordingly.
- Bluetooth-connected patches: Used to record drug application time, duration, and compliance.
- Wearable biosensor-TDDS combinations: For chronic disease management (e.g., hypertension, Parkinson's disease).
- These systems help physicians remotely monitor therapeutic progress and personalize treatment plans, particularly useful in telemedicine and digital health.

3. Nano-Engineered Transdermal Systems

- Nanotechnology continues to revolutionize TDDS by enhancing skin penetration, drug solubility, and targeting efficiency.
- Recent Nanocarriers Used in TDDS:
- Nanostructured lipid carriers (NLCs): Provide sustained release and enhanced skin retention.
- Dendrimers: Highly branched polymers that improve drug solubility and absorption.
- Ethosomes: Ethanol-rich liposomes that improve drug permeability through lipid layers of the skin.
- Transfersomes: Ultra-deformable vesicles that squeeze through skin pores.
- These nanocarriers are particularly effective for drugs with poor solubility, as well as for cosmetic and dermatological applications.

4. 3D-Printed Transdermal Patches

3D printing technology is enabling customized TDDS with precise control over drug dosage, shape, and release kinetics.

Applications:

- Personalized hormone patches
- Pain management patches with variable dose zones
- Pediatric TDDS customized for age, weight, and skin sensitivity

Recent Advancements:

Use of biocompatible filaments like PVA and PLA to create dissolvable microneedle patches

Multi-layer 3D-printed TDDS with sequential drug release profiles

Integration of drug reservoirs and micro-heating circuits for controlled diffusion

5. Hydrogel-Based and Stimuli-Responsive TDDS

Hydrogels are soft, water-swollen polymers that mimic biological tissues and provide a comfortable interface with skin. The latest hydrogel patches are responsive to external stimuli, such as:

Temperature pH, Light, Magnetic fields

Examples:

- Thermo-sensitive hydrogels that release drugs upon skin heating.

- pH responsive TDDS for localized drug release in infected or inflamed skin.
- Light-triggered delivery systems for on-demand release of pain relievers.
- These “smart” patches improve drug targeting and minimize systemic side effects.

6. Iontophoretic and Electroporation Systems

Recent improvements in iontophoresis and electroporation devices have expanded their commercial viability for controlled transdermal drug infusion.
Key Advancements:

- Miniaturized, portable iontophoresis devices for home use.
- Wireless electroporation systems integrated with mobile apps.
- Smart current regulation to reduce irritation and control dosage.

Iontophoretic patches are now being explored for conditions such as migraine, chronic pain, and hormonal therapy.

7. Vaccine Delivery via Transdermal Systems

Transdermal vaccines are now being considered as alternatives to injections for mass immunization, especially in resource-limited or needle-averse populations.

Notable Innovations:

- Microneedle flu vaccine patches undergoing clinical trials.
- COVID-19 vaccine patches for heat-stable, self-administrable delivery.
- Multi-antigen delivery systems for combined immunization.

These systems offer painless, needle-free, and cold-chain independent vaccine solutions, suitable for global public health.

8. Transdermal Delivery of Biologics and Gene Therapy

- A recent innovation involves delivering large biomolecules—like insulin, monoclonal antibodies, and even DNA/RNA—across the skin using:
- Electroporation-enhanced TDDS
- Nanocarriers and lipid-based delivery systems
- Microneedle gene patches for DNA vaccination and CRISPR components
- These methods are being researched for treating genetic diseases, cancer, and autoimmune conditions.

9. Green and Sustainable TDDS Materials

With environmental concerns rising, the development of eco-friendly TDDS has gained traction.
Innovations in Materials:

- Biodegradable polymers like chitosan, alginate, and silk fibroin
- Natural adhesives derived from starch and gums
- Compostable backing layers made from cellulose derivatives
- These sustainable TDDS reduce plastic waste and promote safer disposal.

10. Regulatory-Approved Innovative Products

A number of novel TDDS have received regulatory approvals and are now in clinical use:

- Ionsys®: Iontophoretic fentanyl patch for post-operative pain
- Zecuity®: Migraine patch with iontophoretic delivery of sumatriptan
- Qtrypta™: Microneedle patch for rapid migraine relief
- ZyliDerm®: Nano-enhanced patch for anti-aging skin treatments

References

References Patel, P., & Patil, A. (2021). Transdermal drug delivery systems: A comprehensive review. International Journal of Pharmaceutics, 594(1), 1-18. https://doi.org/10.1016/j.ijpharm.2021.120117

Williams, A. C., & Barry, B. W. (2017). Penetration enhancers. In Transdermal and Topical Drug Delivery (pp. 59-75). CRC Press. https://doi.org/10.1201/9781315164944

Hadgraft, J., & Lane, M. E. (2019). Skin permeability and the transdermal delivery of drugs. In Dermal and Transdermal Drug Delivery: Therapeutic and Cosmetic Applications (2nd ed., pp. 27-43). Springer. https://doi.org/10.1007/978-3-030-10507-3_2

Michaels, A. S., & Chandran, S. P. (2009). A new approach to the design of transdermal drug delivery systems. Journal of Pharmaceutical Sciences, 98(12), 4459-4467. https://doi.org/10.1002/jps.21762

Huang, Y., & Xie, Y. (2018). Microneedle technology for transdermal drug delivery: A review. Journal of Controlled Release, 290, 37-48. https://doi.org/10.1016/j.jconrel.2018.11.008

Shen, Z., & Zhuang, L. (2016). Advances in drug delivery by microneedles. International Journal of Pharmaceutics, 513(1-2), 238-249. https://doi.org/10.1016/j.ijpharm.2016.08.047

Tiwari, G., & Tiwari, R. (2018). A comprehensive review on transdermal drug delivery systems. Biological and Pharmaceutical Bulletin, 41(4), 599-611. https://doi.org/10.1248/bpb.b17-00692

Gao, Y., & Lee, S. H. (2020). Nanotechnology-based transdermal drug delivery systems:

Current trends and future prospects. Nanomedicine: Nanotechnology, Biology and Medicine, 27, 102144. https://doi.org/10.1016/j.nano.2019.102144

Gershkovich, P., & Barenholz, Y. (2017). Transdermal drug delivery systems: Challenges and opportunities. Drug Development and Industrial Pharmacy, 43(10), 1685-1694. https://doi.org/10.1080/03639045.2017.1319689

Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261-1268. https://doi.org/10.1038/nbt.1504

Pillai, O., & Panchagnula, R. (2001). Transdermal drug delivery: An overview. Drug

Development and Industrial Pharmacy, 27(1), 1-16. https://doi.org/10.1081/DDC100002045 Kasting, G. B., & Tansel, M. (2004). Transdermal drug delivery. Informa Healthcare.

McAllister, D. V., & Wang, P. M. (2003). Microfabricated microneedles for transdermal drug delivery. Journal of Controlled Release, 95(3), 227-239. https://doi.org/10.1016/S01683659(03)00325-8

Lee, H., & Park, S. (2017). Transdermal drug delivery using microneedles. Pharmaceutics, 9(4), 32. https://doi.org/10.3390/pharmaceutics9040032

Lee, K., & Lee, D. (2019). Application of microneedles in transdermal drug delivery. Journal of Drug Delivery Science and Technology, 53, 301-309. https://doi.org/10.1016/j.jddst.2019.03.003

Son, H. Y., & Moon, S. H. (2016). Recent advances in transdermal drug delivery. Asian Journal of Pharmaceutical Sciences, 11(5), 577-588. https://doi.org/10.1016/j.ajps.2016.08.003

Zhang, S., & Zhang, Y. (2020). Advances in transdermal drug delivery using nano-based systems. Journal of Nanobiotechnology, 18, 13. https://doi.org/10.1186/s12951-020-06107

Singh, M., & Padhy, A. K. (2018). Transdermal drug delivery: A review. Research Journal of Pharmacy and Technology, 11(10), 4743-4749. https://doi.org/10.5958/0974360X.2018.00857.5

Jain, S., & Sharma, P. (2021). Recent developments in transdermal drug delivery. International Journal of Pharmaceutical Sciences and Research, 12(7), 3963-3975. https://doi.org/10.13040/IJPSR.0975-8232.12(7).3963-75

Kumari, S., & Vyas, S. P. (2016). Transdermal drug delivery systems: A review. International Journal of Drug Development and Research, 8(1), 1-14.

Reddy, K. R., & Ramakrishna, S. (2017). Transdermal drug delivery: A review. Asian Journal of Pharmaceutical and Clinical Research, 10(5), 5-11.

Morrow, D. A., & Thacker, S. (2018). Transdermal systems and their clinical applications. Journal of Clinical Pharmacy and Therapeutics, 43(4), 451-458. https://doi.org/10.1111/jcpt.12647

Prasanth, M. I., & Narayanan, K. (2018). Advances in transdermal drug delivery systems: A review. International Journal of PharmTech Research, 11(6), 246-261.

Verma, D., & Pandey, S. (2015). Development of transdermal drug delivery systems: A review. International Journal of Pharmaceutical Sciences Review and Research, 35(1), 2131.

Lee, H. J., & Lee, S. (2019). New developments in transdermal drug delivery technologies. Frontiers in Pharmacology, 10, 396. https://doi.org/10.3389/fphar.2019.00396

Joshi, A., & Bhutani, G. (2020). Transdermal drug delivery systems: Recent developments and future perspectives. Journal of Drug Delivery Science and Technology, 57, 101703. https://doi.org/10.1016/j.jddst.2020.101703

Shah, S. S., & Joshi, S. D. (2021). Transdermal drug delivery systems: Challenges and strategies for overcoming limitations. Asian Journal of Pharmaceutical Sciences, 16(5), 531-545. https://doi.org/10.1016/j.ajps.2021.05.004

Solanki, S., & Patil, R. (2021). Transdermal drug delivery systems: The future of drug delivery. Indian Journal of Pharmaceutical Sciences, 83(3), 407-418. https://doi.org/10.36468/pharmaceutical-sciences

Bansal, S., & Mishra, D. (2019). Transdermal drug delivery: Emerging trends and challenges. International Journal of Pharmaceutical Investigation, 9(2), 70-78. https://doi.org/10.4103/jphi.JPHI_31_19

Zhai, H., & Maibach, H. I. (2009). Advances in transdermal drug delivery. Dermatologic Therapy, 22(6), 553-559. https://doi.org/10.1111/j.1529-8019.2009.01287.x